Literature DB >> 19959086

Standardisation of molecular monitoring for chronic myeloid leukaemia.

Nicholas C P Cross1.   

Abstract

Molecular monitoring of chronic myeloid leukaemia (CML) patients by real time quantitative reverse transcriptase PCR (RQ-PCR) is of clinical value, but the use of diverse laboratory protocols and units of measurement make it difficult to compare results between and sometimes within centres. This review explores the intrinsic difficulties in standardising the RQ-PCR analysis, summarises the progress that has been made following the proposal for a new International Scale for BCR-ABL measurement and discusses how further improvements are likely to be made.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959086     DOI: 10.1016/j.beha.2009.04.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  22 in total

1.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Authors:  Benjamin Hanfstein; Michael Lauseker; Rüdiger Hehlmann; Susanne Saussele; Philipp Erben; Christian Dietz; Alice Fabarius; Ulrike Proetel; Susanne Schnittger; Claudia Haferlach; Stefan W Krause; Jörg Schubert; Hermann Einsele; Mathias Hänel; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Markus Pfirrmann; Joerg Hasford; Wolf-Karsten Hofmann; Andreas Hochhaus; Martin C Müller
Journal:  Haematologica       Date:  2014-05-16       Impact factor: 9.941

Review 2.  Allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  Jiří Pavlů; Jane F Apperley
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

3.  Quality control methods for optimal BCR-ABL1 clinical testing in human whole blood samples.

Authors:  Lauren M Stanoszek; Erin L Crawford; Thomas M Blomquist; Jessica A Warns; Paige F S Willey; James C Willey
Journal:  J Mol Diagn       Date:  2013-03-27       Impact factor: 5.568

Review 4.  Molecular monitoring.

Authors:  Simona Soverini; Gianantonio Rosti; Michele Baccarani; Giovanni Martinelli
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

5.  Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Authors:  B Hanfstein; V Shlyakhto; M Lauseker; R Hehlmann; S Saussele; C Dietz; P Erben; A Fabarius; U Proetel; S Schnittger; S W Krause; J Schubert; H Einsele; M Hänel; J Dengler; C Falge; L Kanz; A Neubauer; M Kneba; F Stegelmann; M Pfreundschuh; C F Waller; K Spiekermann; G M Baerlocher; M Pfirrmann; J Hasford; W-K Hofmann; A Hochhaus; M C Müller
Journal:  Leukemia       Date:  2014-05-06       Impact factor: 11.528

6.  Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP).

Authors:  Velu Nair; Ajay Sharma; Jyoti Kotwal; M Bhikshapathy; D K Mishra; Satyaranjan Das; Sanjeevan Sharma; Rajan Kapoor; Jasjit Singh; Vivek Nair; Y Uday; Atul Kotwal
Journal:  Med J Armed Forces India       Date:  2014-10-16

Review 7.  Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Authors:  Simona Soverini; Caterina De Benedittis; Manuela Mancini; Giovanni Martinelli
Journal:  Oncologist       Date:  2016-03-31

8.  Chronic Myelogenous Leukemia, Version 1.2014.

Authors:  Susan O'Brien; Jerald P Radich; Camille N Abboud; Mojtaba Akhtari; Jessica K Altman; Ellin Berman; Daniel J DeAngelo; Michael Deininger; Steven Devine; Amir T Fathi; Jason Gotlib; Madan Jagasia; Patricia Kropf; Joseph O Moore; Arnel Pallera; Javier Pinilla-Ibarz; Vishnu Vb Reddy; Neil P Shah; B Douglas Smith; David S Snyder; Meir Wetzler; Kristina Gregory; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2013-11       Impact factor: 11.908

9.  Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.

Authors:  David L Deremer; Katerina Katsanevas; Celalettin Ustun
Journal:  Cancer Manag Res       Date:  2011-03-10       Impact factor: 3.989

10.  On the Power of Additional and Complex Chromosomal Aberrations in CML.

Authors:  Karin M Greulich-Bode; Barbara Heinze
Journal:  Curr Genomics       Date:  2012-09       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.